A very bullish analyst move was the news generally responsible for Summit Therapeutics ' ( SMMT -3.62%) healthy mid-week ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

Evercore ISI initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $30 price target The firm sees lead asset, ...

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Summit Therapeutics (SMMT – Research Report), with a ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $17.0 for Summit Therapeutics over the last 3 months.

Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of the prior year. It also announced a collaboration with Pfizer.

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other best growth stocks to invest in according to analysts. Companies experiencing ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 ...